Ionis Pharmaceuticals
IONS
493 hedge funds and large institutions have $13B invested in Ionis Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 74 funds opening new positions, 177 increasing their positions, 156 reducing their positions, and 65 closing their positions.
14% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 65
13% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 156
8% more funds holding in top 10
Funds holding in top 10: 13 → 14 (+1)
0% more funds holding
Funds holding: 491 → 493 (+2)
0.72% less ownership
Funds ownership: 105.2% → 104.48% (-0.72%)
2% less call options, than puts
Call options by funds: $141M | Put options by funds: $144M
4% less capital invested
Capital invested by funds: $13.5B → $13B (-$512M)
Top Buyers
| 1 |
Capital World Investors
Los Angeles,
California
|
+$255M |
| 2 |
Two Sigma Investments
New York
|
+$252M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$212M |
| 4 |
Millennium Management
New York
|
+$75.6M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$69.2M |
Top Sellers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$235M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$233M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$94.1M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$58M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$44.1M |
IONS Hedge Fund Activity: Q1 2026 in Review
493 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2026, worth a combined $13B — down 3.8% from $13.5B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new IONS positions and 65 closed out — a net gain of 9 holders — while 177 added to existing stakes and 156 trimmed.
The largest buyer was Capital World Investors, adding an estimated $255M. The largest seller was Bellevue Group, cutting an estimated $235M.
- 493 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2026, up from 491 in Q4 2025.
- Funds reported $13B of Ionis Pharmaceuticals stock for Q1 2026, down 3.8% quarter-over-quarter.
- 74 funds opened new Ionis Pharmaceuticals positions in Q1 2026 and 65 closed out, a net change of +9 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2026 was Capital World Investors, an estimated $255M added.
- The largest Ionis Pharmaceuticals seller in Q1 2026 was Bellevue Group, an estimated $235M sold.
Based on aggregated 13F filings for Q1 2026.